Back to Browse Journals » Open Access Emergency Medicine » Volume 2

Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole

Authors Bruno Mégarbane

Published 26 August 2010 Volume 2010:2 Pages 67—75


Review by Single-blind

Peer reviewer comments 2

Bruno Mégarbane
Réanimation Médicale et Toxicologique, Hôpital Lariboisière and Université Paris-Diderot, Paris, France
Abstract: Ethylene glycol (EG) and methanol are responsible for life-threatening poisonings. Fomepizole, a potent alcohol dehydrogenase (ADH) inhibitor, is an efficient and safe antidote that prevents or reduces toxic EG and methanol metabolism. Although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. Treatment should be started as soon as possible, based on history and initial findings including anion gap metabolic acidosis, while awaiting measurement of alcohol concentration. Administration is easy (15 mg/kg-loading dose, either intravenously or orally, independent of alcohol concentration, followed by intermittent 10 mg/kg-doses every 12 hours until alcohol concentrations are <30 mg/dl). There is no need to monitor fomepizole concentrations. Administered early, fomepizole prevents EG-related renal failure and methanol-related visual and neurological injuries. When administered prior to the onset of significant acidosis or organ injury, fomepizole may obviate the need for hemodialysis. When dialysis is indicated, 1 mg/kg/h-continuous infusion should be provided to compensate for its elimination. Side-effects are rarely serious and with a lower occurrence than ethanol. Fomepizole is contraindicated in case of allergy to pyrazoles. It is both efficacious and safe in the pediatric population, but is not recommended during pregnancy. In conclusion, fomepizole is an effective and safe first-line antidote for EG and methanol intoxications.
Keywords: ethanol, hemodialysis, metabolic acidosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease

Andelid K, Andersson A, Yoshihara S, Åhrén C, Jirholt P, Ekberg-Jansson A, Lindén A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1253-1263

Published Date: 30 June 2015

Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

Zhang JQ, Zhang JQ, Liu H, Zhao ZH, Fang LZ, Liu L, Fu WP, Shu JK, Feng JG, Dai LM

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:917-923

Published Date: 13 May 2015

Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells

Zhang H, Liu G, Zeng X, Wu Y, Yang C, Mei L, Wang Z, Huang L

International Journal of Nanomedicine 2015, 10:2461-2473

Published Date: 27 March 2015

Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study

Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:603-611

Published Date: 18 March 2015

Preparation and in vitro antitumor effects of cytosine arabinoside-loaded genipin-poly-L-glutamic acid-modified bacterial magnetosomes

Liu YG, Dai QL, Wang SB, Deng QJ, Wu WG, Chen AZ

International Journal of Nanomedicine 2015, 10:1387-1397

Published Date: 17 February 2015

Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules

Clavreul A, Montagu A, Lainé AL, Tétaud C, Lautram N, Franconi F, Passirani C, Vessières A, Montero-Menei CN, Menei P

International Journal of Nanomedicine 2015, 10:1259-1271

Published Date: 12 February 2015